Figure 8 | Scientific Reports

Figure 8

From: Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Figure 8

Bivalent SARS-CoV-2 RBD-cCPE/influenza H1-HA1-cCPE induces SARS-CoV-2 pseudovirus (Delta variant B.1.617.2) neutralizing antibodies in NALF, BALF and serum. Mice (n = 5) were prime-boost immunized intranasally (days 0 and 21) with bivalent SARS-CoV-2 RBD-cCPE/Influenza H1-HA1-cCPE vaccine, adjuvanted with Riboxxim. NALF, BALF and sera were obtained on day 28, 1 week after the boost, diluted in tenfold steps, and assayed for neutralization of SARS-CoV-2 pseudoviruses. The spike protein sequence was derived from SARS-CoV-2 strain B.1.617.2.

Back to article page